Trump Launches TrumpRx Website Promising Lower Drug Prices

On Thursday evening, February 6, 2026, President Donald Trump stood at the White House to unveil his administration’s latest attempt to tackle one of Americans’ most persistent worries: the high cost of prescription drugs. With Centers for Medicare and Medicaid Services Administrator Dr. Mehmet Oz and National Design Studio Director Joe Gebbia by his side, Trump launched TrumpRx.gov, a government-run website designed to help U.S. consumers find lower-priced brand-name medications. The event, which had been teased for months and delayed briefly in January, drew national attention—and plenty of debate.

“You’re going to save a fortune,” Trump declared at the launch, according to ABC News. “And this is also so good for overall health care.” The White House press secretary, Karoline Leavitt, echoed this optimism earlier in the day, describing TrumpRx as “a state-of-the-art website for American consumers to purchase low-cost prescription drugs.” She added, “This historic announcement will save millions of Americans their hard-earned money.”

The TrumpRx platform is part of a broader “most favored nation” initiative, first announced by Trump back in September 2025. The goal? To pressure pharmaceutical companies into charging U.S. patients no more than what they charge in other wealthy countries. As part of this effort, the administration negotiated pricing deals with more than a dozen major drugmakers, including Pfizer, Eli Lilly, Novo Nordisk, AstraZeneca, and EMD Serano. Pfizer was the first to strike a deal, pledging discounts up to 85% on certain medications offered through TrumpRx, with an average savings of about 50% compared to current private-sector list prices, according to Stat News.

At launch, TrumpRx listed discounted cash prices on 43 brand-name medications, including popular weight loss drugs like Zepbound and Wegovy, as well as treatments for diabetes, migraines, hepatitis C, and arthritis. For instance, the migraine drug Zavzpret dropped from $1,189 to $549 through the platform. Some drugs, such as the blood thinner Plavix, were available for as little as $16 per month, while others, like the hepatitis C drug Epclusa, cost $2,425.

But here’s the catch: TrumpRx does not sell drugs directly. Instead, the website acts as a portal, connecting users to pharmaceutical company websites or offering coupons that can be redeemed at participating pharmacies. The technology behind TrumpRx borrows from platforms like GoodRx, which already help consumers compare prices and find discounts. As Dr. Oz explained to ABC News, “We don’t sell the drugs. This is a government website. We are allowing everybody transparency into what these drugs cost.” He added, “Any company that sells the drugs can put their products on the website, and you can go there and say, 'You know, in my area, I can buy for that price.' And they can hit the button and buy from whoever is selling it.”

For Americans without insurance, or those paying entirely out of pocket for medications not covered by insurance—such as fertility treatments, weight loss drugs, or cosmetic injectables—TrumpRx may offer meaningful savings. According to the University of Washington’s Sean Sullivan and Ryan Hansen, writing in Stat, the “real winners” may be these cash-paying patients, as well as the pharmaceutical companies themselves, which can use the platform to maintain higher prices overall while appearing generous through selective discounting.

Yet for the vast majority of Americans—about 84% of whom have prescription drug coverage, according to the Department of Health and Human Services—the benefits are less clear. Juliette Cubanski, deputy director of the program on Medicare Policy at KFF, told NBC News, “There’s no clear advantage for most people to use TrumpRx to purchase their medications.” She explained that for insured patients, it’s hard for direct-to-consumer prices to beat the cost-sharing amounts they pay using their insurance. In fact, TrumpRx itself warns users: “If you have insurance, check your co-pay first—it may be even lower.” Moreover, purchases made through TrumpRx typically don’t count toward insurance deductibles or out-of-pocket maximums.

There’s another wrinkle. Many of the drugs featured on TrumpRx are already widely covered by insurance, and some are available as inexpensive generics—options that are not included on the site, which focuses exclusively on brand-name medications. With generic drugs making up about 90% of all prescriptions in the U.S., according to the Food and Drug Administration, the platform’s reach is inherently limited. As Rachel Sachs, a law professor at Washington University in St. Louis, told The New York Times, “There may be patients who think this is a good deal and then end up financially worse off.” She cautioned that patients with low out-of-pocket costs through their insurance could waste hundreds of dollars annually by paying cash through TrumpRx instead.

The Trump administration has promoted the program as a bold step toward price transparency and consumer empowerment. Trump last month released his “Great Healthcare Plan,” which called on Congress to codify the “most favored nation” initiative, increase price transparency, and hold insurance companies accountable. However, the plan was criticized for lacking specifics, and many details about TrumpRx remain murky—including how long the discounts will last and the terms of the negotiated deals. The administration has said it secured price cuts in exchange for tariff relief, but consumer advocacy group Public Citizen filed a Freedom of Information Act lawsuit in January 2026 seeking documents related to these agreements.

Not everyone is convinced TrumpRx is the answer to America’s drug pricing woes. Some health policy experts have called the program a “distraction” from deeper structural problems in the U.S. drug market. They argue that while the website may offer relief to some, it does little to address the root causes of high prescription drug costs for most Americans. Meanwhile, lawmakers have raised concerns about the legality of the platform. In January, Democratic Senators Dick Durbin, Peter Welch, and Elizabeth Warren sent a letter to the Department of Health and Human Services’ Office of Inspector General, warning that TrumpRx might violate federal anti-kickback laws and expressing frustration over a lack of transparency and oversight.

Despite these criticisms, the demand for solutions is undeniable. A recent KFF poll found that two-thirds of U.S. adults worry about affording health care for themselves and their families, outranking other concerns like gas and groceries. More than half expect health care to become less affordable in the coming year. The same survey revealed that two-thirds of Americans disapproved of Congress allowing enhanced Affordable Care Act tax credits to expire, a move expected to increase premium costs for millions.

Direct-to-consumer prescription drug platforms are not new. Mark Cuban’s Cost Plus Drugs, launched in 2022, focuses on providing lower-cost generics. Drugmakers like Novo Nordisk and Eli Lilly have also introduced their own cash-pay websites for medications such as Wegovy and Zepbound. According to Novo Nordisk, 30% of Wegovy users now pay out of pocket, while Eli Lilly reports about 1 million patients have used its Zepbound platform since launch.

As the dust settles on TrumpRx’s debut, questions linger about its long-term impact and whether it will truly deliver on the promise of lower drug costs for all Americans. For now, it’s a new tool in the ever-complex landscape of U.S. health care—one that may help some, but not all, in the ongoing struggle to afford the medicines they need.